Skip to main content

afatinib

Generic: afatinib·Brand: Gilotrif

afatinib: 7 clinical trials tracked.

afatinib evidence translation

What we can confirm

7 tracked trials

No verified listed developer

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about afatinib, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence8 indications · 3 study sponsors
Clinical Trials (7)

A Prospective Randomized Controlled Trial Comparing Low-Dose Radiotherapy Combined With Targeted Therapy and Immunotherapy Versus Targeted Therapy and Immunotherapy Alone as Neoadjuvant Therapy in Patients With Operable Head and Neck Squamous Cell Carcinoma.

NCT07040956·Phase 2
Recruiting

Primary endpoint: Major Pathologic Response

InterventionalRandomizedopen98 targetStarted 2025-06Completion 2026-071 site · ChinaWest China Hospital

Neoadjuvant Low-Dose Radiotherapy Plus Targeted Therapy and Immunotherapy vs. Targeted Therapy Plus Immunotherapy in Resectable Head and Neck Squamous Cell Carcinoma: A Prospective Randomized Controlled Trial

NCT06804850·Phase 2
Withdrawn

Primary endpoint: Major Pathologic Response

InterventionalRandomizedopen0 targetStarted 2025-01Completion 2026-06West China Hospital

A Phase Ia/Ib Study of the Combination of the FGFR Inhibitor Pemigatinib and the EGFR Inhibitor Afatinib in Advanced Refractory Solid Tumors

NCT06302621·Phase 1
Recruiting

Primary endpoint: Maximum tolerated dose (MTD)

Interventionalopen70 targetStarted 2024-04Completion 2027-121 site · United StatesMassachusetts General Hospital

Phase 2 Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma

NCT05070403·Phase 2·GHRS
Active, not recruiting

Primary endpoint: Overall Response Rate

Interventionalopen35 targetStarted 2021-10Completion 2028-031 site · United StatesH. Lee Moffitt Cancer Center and Research Institute

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL-1

NCT03785249·Phase 1/Phase 2·MRTX

Primary endpoint: Characterize the safety of MRTX849 in patients having advanced solid tumor malignancies with KRAS G12C mutation

Interventionalopen731 targetStarted 2019-01Completion 2026-1250 sites · United StatesMirati Therapeutics Inc.

A Dutch National Study on Behalf of the CPCT to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to Determine the Potential Efficacy in Treatment of Advanced Cancers With a Known Molecular Profile

NCT02925234·Phase 2
Recruiting

Primary endpoint: Percentage of patients that are treated based on their molecular tumor profile

Interventionalopen1,550 targetStarted 2016-08Completion 2027-1236 sites · NetherlandsThe Netherlands Cancer Institute

Molecular Analysis for Therapy Choice (MATCH)

NCT02465060·Phase 2·ADMA
Active, not recruiting

Primary endpoint: Objective response rate (ORR)

Interventionalopen6,452 targetStarted 2015-08Completion 2026-1250 sites · United StatesNational Cancer Institute (NCI)